Latest Breaking News On - Biond biologics ltd - Page 1 : vimarsana.com
Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Investegate |Oxford Nanopore Tech Announcements | Oxford Nanopore Tech: Expected Intention to Float
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Share this article
MISGAV, Israel, Jan. 12, 2021 /PRNewswire/
Biond Biologics Ltd. ( Biond or the Company ), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that it has entered into an exclusive worldwide license agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY), for the development and commercialization of BND-22.
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors. ILT2, a member of the ILT family of immuno-modulating receptors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules including HLA-G, an immunosuppressive protein expressed by multiple tumor types.
Sanofi, Israel s Biond Biologics to collaborate on new cancer drug Reuters 12/01/2021 © Reuters/Charles Platiau FILE PHOTO: Sanofi logo is seen in Paris
JERUSALEM (Reuters) - Israel s Biond Biologics Ltd said on Tuesday it had forged an exclusive global licence agreement, potentially worth more than $1 billion, with French drugmaker Sanofi for the development and commercialization of its BND-22 cancer drug.
Biond, a privately-held biopharmaceutical company, developing novel immunotherapies for cancer, said that it will receive a $125 million upfront payment in cash under the deal.
It will also be entitled to receive more than $1 billion in development, regulatory, and sales milestones, as well as tiered double-digit royalty payments, the company said.